VedaBio to Revolutionize Molecular Detection after Tenure as LabSimply at EnterpriseWorks
VedaBio, a biotechnology company leading a paradigm-shift in molecular detection, launched on October 17, 2023, with initial funding of over $40 million.
This company has roots at the University of Illinois-Urbana Champaign and Research Park: VedaBio was formerly known as LabSimply and operated out of EnterpriseWorks from 2021 to 2022.
CEO and Co-Founder Anrup Ganguli, PhD, developed multiple research platforms during his time at university in the lab of Professor Rashid Bashir, PhD, Professor of Bioengineering and current Dean of the Grainger College of Engineering.
VedaBio is revolutionizing molecular biology with its breakthrough platform for near-instant molecular detection of multiplexed analytes, delivering best-in-class accuracy without the need for target amplification. Their CRISPR Cascade™ platform is poised to emerge as a new gold standard tool to empower decision-making across multiple industries.
In the official press release, Ganguli explains that the CRISPR Cascade reaction provides “a platform that delivers near-instant molecular detection of highly multiplexed analytes with best-in-class accuracy, all without the need for target amplification.”
He has high hopes for VedaBio, believing “it is poised to emerge as a future gold standard for molecular detection, empowering major advances across multiple applications including research and industrial tools, diagnostics and therapeutics.”
To learn more about VedaBio, read the official press release on the VedaBio website.